Adult Protocols

Last updated December 2011

Cancer-related research projects by attending physicians on staff
within Inova Cancer Services and Inova Women's Services

This list of open research trials is meant to be a general information resource only.
This information is updated on a regular basis. It should not replace information given by your physician. These studies may close without warning.

In addition to the consent forms for these studies, additional general disease information
can be found at www.cancer.gov. Inova Research Center provides general information
regarding clinical trials for patients. The U.S. government has a clinical trial website
with helpful information for patients. It allows people to look for trials in specific therapeutic
areas: www.clinicaltrials.gov. The National Cancer Institute also has trial search engines and
information on clinical trials.

For questions regarding the status of an individual study, please contact the person listed with
each individual study.

Translational Research

Protocol/Organization	Study Title/Purpose	Status
Inova/George Mason University Transitional Research Institute	Cancer Molecular Profiling Project Purpose: To study the phosphoproteomic profile of brain, ovarian, colorectal, liver, lung and hematogenous malignancies to classify disease and develop treatments using microarray technology Principal Investigator: Kirsten Edmiston, MD Contact Person: Heather Huryk, 703-776-4021	Open
International Genomics Consortium (IGC)	The Expression Project for Oncology (expO) Purpose: To perform gene expression analysis on breast, lung, colon, ovary and prostate tumors and make all data publicly available with no intellectual property restrictions. Principal Investigator: Kirsten Edmiston, MD Contact person: Heather Huryk, 703-776-4021	Open

Acute Myeloid Leukemia

Protocol/Organization	Study Title/Purpose	Status
GSK PMA112509	A Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia after MDS (sAML/MDS) Principal Investigator: John Feigert, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Bladder

Protocol/Organization	Study Title/Purpose	Status
US Oncology 09-217	An Open-label, Multi-center, Randomized Phase II Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter or Renal Pelvis Following Disease Progression on Firsty-line Platinum-based Therapy Principal Investigator:Alexander Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Brain – Glioblastoma

Protocol/Organization	Study Title/Purpose	Status
RTOG 0825	A Phase III, Double-Blind, Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Principal Investigator: Jane Grayson, MD Contact Person: Arletta van Breda, RN, MSN, CCRC, CIP, 704-503-7760 or 703-504-7950	Open
RTOG 0837	A Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed Glioblastoma Principal Investigator: Samir Kanani, MD Contact Person: Heather Huryk, 703-776-4021	Open

Site: Breast – Ductal Carcinoma in Situ

Protocol/Organization	Study Title/Purpose	Status
Inova/George Mason University	Preventing Invasive Breast Neoplasia with Chloroquine (PINC) Trial Purpose: To study the use of chloroquine in the treatment of ductal carcinoma in situ (DCIS) and in prevention of invasive breast cancer in patients diagnosed with DCIS. Principal Investigator: Kirsten Edmiston, MD Contact Person: Heather Huryk, 703-776-4021	Open

Site: Breast – Neoadjuvant

Protocol/Organization	Study Title/Purpose	Status
ISPY-2	ISPY-2 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis Purpose: To study multiple novel agents in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Principal Investigator: Kirsten Edmiston, MD Contact Person: Heather Huryk, 703-776-4021; Stacey Banks, 703-208-3148; Kristen Smiley, RN, 703-720-5210	Open

Site: Breast – Adjuvant

Protocol/Organization	Study Title/Purpose	Status
US Oncology 07-132	A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC, for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Principal Investigator: Nicholas Robert, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Breast – Locally Recurrent or Metastatic

Protocol/Organization	Study Title/Purpose	Status
CALGB 40502	A Randomized, Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixebepilone Combined with Bevacizumab, as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer Principal Investigator: Mary Wilkinson, MD Contact Person: Kristen Smiley, RN, 703-720-5210	Open
CALGB 70604	A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer Principal Investigator: Mary Wilkinson, MD Contact Person: Kristen Smiley, RN, 703-720-5210	Open
US Oncology 08-223	A Randomized, Phase III, Double-Blind, Placebo-Controlled Multi-Center Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine, in Pretreated Women with HER2/neu Over-Expressing Locally Advanced or Metastatic Breast Cancer Principal Investigator: Nicholas Robert, MD Contact Person: Stacey Banks, 703-208-3148	Open
US Oncology 09-097	A Randomized, Phase III, Open-Label Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab Plus Chemotherapy, in Subjects with HER2- Positive Metastatic Breast Cancer Principal Investigator: Nicholas Robert, MD Contact Person: Stacey Banks, 703-208-3148	Open
US Oncology 09-185	2010EAP: An Open-Label, Expanded Access Protocol of Iniparib in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer Principal Investigator: Nicholas Robert, MD Contact Person: Stacey Banks, 703-208-3148	Open
SIDE-OUT	A Pilot Study Utilizing Molecular Profiling by IHC, FISH, DNA Microarray, and Reverse Phase Protein Microarray (RPMA) of Patients' Tumors to Find Potential Targets and Select Treatments, for Patients with Metastatic Breast Cancer Principal Investigator: Nicholas Robert, MD Contact Person: Stacey Banks, 703-208-3148	Open
TRIO 018 (A5481003)	Phase I/II, Open-Label, Randomized Study of the Safety, Efficacy, and Pharmacokinetics of Letrozole Plus PD 0332991 (Oral CDK 4/6 inhibitor) and Letrozole Single Agent, for the First-Line Treatment of ER Positive, HER2 Negative Advanced Breast Cancer in Postmenopausal Women Principal Investigator: Nicholas Robert, MD Contact Person: Stacey Banks, 703-208-3148	Open
Mayo Clinic MC0738	The Effect of Anti-depressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study Principal Investigator: Neelima Denduluri, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: CLL

Protocol/Organization	Study Title/Purpose	Status
US Oncology 11-078	An Open-Label, Multi-Center, Randomized Phase II Trial Comparing the Efficacy, Safety, and Pharmacokinetics of GA101 1000 MG versus 2000 MG in Patients with Previously Untreated Chronic Lymphocytic Leukemia Principal Investigator: Dipti Patel-Donnelly, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Metastatic Colorectal Cancer

Protocol/Organization	Study Title/Purpose	Status
CALGB/SWOG C80702	A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer Principal Investigator: Mary Wilkinson, MD Contact Person: Kristen Smiley, RN, 703-720-5210	Open
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver	Metastasis from Colon Cancer with Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemothery, and Anti-Angiogenic Therapy Purpose: The main purpose of this study is to find out if the combination of TACE and intravenous chemotherapy is safe as well as more effective than intravenous chemotherapy alone. Watch our stage 4 colon cancer or rectal cancer spread to the liver study videos. Principal Investigator: Jim Papadouris, MD Contact Person: Arletta van Breda, RN, MSN, CCRC, CIP, 703-504-7760 or 703-504-7950	Open
US Oncology 10-101	A Randomized, Double-Blind, Multi-Center, Phase III Study of Irinotecan, Folinic Acid and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients with Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy with Bevacizumab, Oxaliplatin and a Fluoropyrimidine Principal Investigator: Alexandra Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open
US Oncology 11-072	Phase I/II Study of PX-866 and Cetuximab for CRC and SCCHN Principal Investigator: Alexandra Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Endometrium (Uterine)

Protocol/Organization	Study Title/Purpose	Status
Walter Reed E39	Phase Ib Trial of Folate Binding Protein (FBP) Peptide (E39)Vaccine in Ovarian and Endometrial Cancer Patients Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
Walter Reed	Tissue and Data Acquisition for the Study of Gynecologic Disease Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
Precision Therapeutics	A Non-Interventional, Longitudinal, Multi-Center Initiative Examining Outcomes Associated with the Use of the ChemoFx Assay in Solid Tumor Malignancies Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
	Natural History of Urinary Symptoms in Women Receiving Paclitaxel/Carboplatin for Treatment of Gynecologic Cancers Principal Investigator: Walter von Pechmann, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
NCI	In Vitro Evaluation of Binding of Optical Imaging Compounds to Human Epithelial Ovarian Adenocarcinoma Tissue Specimens Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
Caris Dx	A Registry of the Target Now Test Results (Biomarker Expression Patterns) for Evaluation of Correlation with Clinical Outcomes for Cancer Patients Principal Investigator: Annette Bicher, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open

Site: Esophagus

Protocol/Organization	Study Title/Purpose	Status
RTOG 0436	A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Patients with Esophageal Cancer Who are Treated without Surgery Principal Investigator: Jane Grayson, MD Contact Person: Arletta van Breda, RN, MSN, CCRC, CIP, 703-504-7901	Open

Site: Interventional Radiology

Protocol/Organization	Study Title/Purpose	Status
	A Humanitarian Device Exemption Treatment Protocol of TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma and Tumors Metastatic to the Liver Principal Investigator: Calvin Neithamer, MD, FACR Contact Person: Heather Huryk, 703-776-4021	Open

Site: Lung

Protocol/Organization	Study Title/Purpose	Status
US Oncology 08-035	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks, in Anemic Subjects with Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open
GSK MAGRIT 109493	A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open
Merck START EMR 63325-001START	A Multi-Center, Phase III, Randomized, Double-Blind Placebo Controlled Study of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine), in Non-Small Cell Lung Cancer (NSCLC) Subjects with Unresectable Stage III Disease Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Closed
US Oncology 10-061	A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open
CP11-0806	A Randomized, Multi-Center, Open-Label, Phase III Study of Gemcitabine-Cisplatin Chemotherapy Plus IMC-11F8 versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients with Squamous Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open
US Oncology 10-090	A Phase III Randomized, Double-Blind, Placebo Controlled Study of ARQ 197 Plus Erlotinib versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open
US Oncology 11-064	A Phase II, Open-Lable, Multi-Center, Randomized Study to ASsess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC Stage III Bwet-IV) Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Melanoma

Protocol/Organization	Study Title/Purpose	Status
US Oncology 10-052	An Open-Label, 2-Cohort, Multi-Center Phase II Study of E7080 in Previously Treated Subjects with Unresectable Stage III or Stage IV Melanoma Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Multiple Myeloma

Protocol/Organization	Study Title/Purpose	Status
Multiple Myeloma Research Foundation MMRF 11-001	A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM)Patients to Assess the Relationship Between Patient Outcomes, Treatment Options and Molecular Profiles Principal Investigator: Gregory Orloff, MD Contact Person: Stacey Banks, 703-208-3148	Open
Merck V212-001	A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-center Clinical Trial to Study the Safety, Tolerability, Efficacy and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs) Principal Investigator: Gregory Orloff, MD Contact Person: Stacey Banks, 703-208-3148	Open
Novartis CLBH589D2308	A Multi-Center, Randomized, Double-Blind, Placebo Controlled Phase III Study of Panobinostat in Combination with Bortezomib and Dexamethasone in Patients wtih Relapsed Multiple Myeloma Principal Investigator: Mary Wilkinson, MD Contact Person: Kristen Smiley, RN, 703-720-5210	Open
Oncotherapeutics IST-CAR-5168	A Phase I/II Study of Carflizomib as a Replacement for Bortezomib for Multiple Myeloma Patients Failing Borezomib-Containing Regimens Principal Investigator: Dipti Patel-Donnelly, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Myelodysplastic Syndrome

Protocol/Organization	Study Title/Purpose	Status
GSK PMA112509	A Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia after MDS (sAML/MDS) Principal Investigator: John Feigert, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Nonlymphomatous Cancers

Protocol/Organization	Study Title/Purpose	Status
US Oncology 11-107	Screening Protocol to Detect Tumor Antigen Expression Required for Enrollment on Clinical Research Protocols of Antibody-Directed Therapy Principal Investigator: Dipti Patel-Donnelly, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Ovarian Cancer

Protocol/Organization	Study Title/Purpose	Status
Walter Reed E39	Phase lb Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
GOG0212	A Randomized, Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
GOG0252	A Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
GOG0262	A Randomized, Phase III Trial of Every 3 Weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Beyacizumab in the Treatment of Primary Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
Amgen	A Phase III, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women with Recurrent, Partially Platinum Sensitive or Resistance Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
Morphotek MORAb003-003	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (Farletuzumab) in Combination with Paclitaxel Therapy in Subjects with First Platinum-Resistant or Refractory Relapsed Ovarian Cancer Principal Investigator: Annette Bicher, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
Morphotek MORAb003-004	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-Sensitive Ovarian Cancer in First Relapse Principal Investigator: Annette Bicher, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
Walter Reed	Tissue and Data Acquisition for the Study of Gynecologic Disease Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
Precision Therapeutics	A Non-Interventional, Longitudinal, Multi-Center Initiative Examining Outcomes Associated with the Use of the ChemoFx Assay in Solid Tumor Malignancies Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
	Natural History of Urinary Symptoms in Women Receiving Paclitaxel/Carboplatin for Treatment of Gynecologic Cancers Principal Investigator: Walter von Pechmann, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
NCI	In Vitro Evaluation of Binding of Optical Imaging Compounds to Human Epithelial Ovarian Adenocarcinoma Tissue Specimens Principal Investigator: John Elkas, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open
Caris Dx	A Registry of the Target Now Test Results (Biomarker Expression Patterns) for Evaluation of Correlation with Clinical Outcomes for Cancer Patients Principal Investigator: Annette Bicher, MD Contact Person: Angela Alonge, BS, 703-698-7100, ext. 344	Open

Site: Pancreas

Protocol/Organization	Study Title/Purpose	Status
US Oncology 05-129	A Randomized Phase III Study of Weekly ABI-007 Plus Gemciabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Prostate

Protocol/Organization	Study Title/Purpose	Status
US Oncology 09-073	A Phase III Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancer Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open
RTOG 0534	A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy Principal Investigator: Matt Poggi, MD Contact Person: Arletta van Breda, RN, MSN, CCRC, CIP, 703-503-7760 or703-504-7950	Open
RTOG 0815	A Phase III, Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short Term Androgen Deprivation Therapy for Patients with Intermediate Risk Prostate Cancer Principal Investigator: Matt Poggi, MD Contact Person: Arletta van Breda, RN, MSN, CCRC, CIP, 703-503-7760 or703-504-7950	Open
US oncology 10-278	A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate-Resistant Prostate Cancer Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Sarcoma

Protocol/Organization	Study Title/Purpose	Status
US Oncology 10-237	A Phase III Multi-Center, International, Randomized, Double-Blind, Placebo-Controlled Study of Doxorubicin Plus Palifosfamide-tris versus Doxorubicin Plus Placebo in Patients with Front-Line Metastatic Soft Tissue Sarcoma Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open
Johnson & Johnson ET743-SAR-3007	A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazzine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open

Site: Squamous Cell Carcinoma of the Head and Neck

Protocol/Organization	Study Title/Purpose	Status
US Oncology 11-072	Phase I/II study of PX-866 and Cetuximab (CRC and SCCHN) Principal Investigator: Alex Spira, MD Contact Person: Stacey Banks, 703-208-3148	Open

A	B	C	D	E	F	G	H	I
J	K	L	M	N	O	P	Q	R
S	T	U	V	W	X	Y	Z	All

Adult Protocols

Cancer-related research projects by attending physicians on staff within Inova Cancer Services and Inova Women's Services

Cancer-related research projects by attending physicians on staff
within Inova Cancer Services and Inova Women's Services